Aikili Biosystems Inc — Department of Health and Human Services SBIR Phase I: 102

Description

Molecular analyses of cancer cells are essential in establishing diagnoses and guiding available treatments. Conventional tissue biopsies, while providing key information on tissue architecture, are associated with morbidity and high cost and therefore are not performed as frequently as would be clinically desirable. An alternative to cutting core biopsy guns are fine needle aspirations (FNAs), which can be performed with minimal intervention and allow for less invasive and/or repeated sampling from small lesions. However, workup of FNA specimens remains challenging using conventional cytology and immunohistochemistry. To address these barriers, Aikili Biosystems seeks to enable same-day diagnostic workup of FNA samples using a proprietary “FAST” assay and automated image cytometer. A key component of Aikiliandapos;s technology is our proprietary cell cycling method (FAST), which builds upon and expands previous assay capabilities (4- channel multiplexing) to over 20-40 biomarkers; it is coupled with our image cytometer, a stand-alone diagnostic platform capable of automated cancer cell classification in andlt;2 hours. Building upon initial development and pre-clinical validation, in Aim 1, we will validate FAST antibody probes in andgt;15 cancer markers, integrate sample processing with Aikiliandapos;s cytometry system and analyze associated images using the device. In Aim 2, we will evaluate the benefit of the integrated technology for rapid, same-day analysis of clinical samples, specifically lymphoma FNA samples (n = 40) stained with FAST-linker modified antibody probes. Phase I will be deemed successful when Aikiliandapos;s system reliably detects and classifies lymphoma cells compared to gold standards. Successful completion of Phase I will lay the foundation for a Phase II application for clinical testing and manufacture of cytometry systems and commercial cartridges for multiple cancers. This platform has potential to transform cellular diagnostics and pathology workflows through rapid, same-day analyses of minimally invasive FNAs; its robust analyses of pharmacodynamic markers has potential to enable development of new, clinically meaningful biomarkers that can be used to advance drug development.We have developed a standalone, automated diagnostic platform that allows deep, single cell profiling of scant cellular samples from multiple cancer types by profiling dozens of markers per cell. Our approach aims to transform cellular diagnostics through rapid, same-day analyses of clinical samples, as well as augment pathology workflows by greatly expanding on the capabilities of conventional cytology. By enabling robust analyses of pharmacodynamic markers, our platform also has potential to play a pivotal role in rapidly accruing patients into cancer clinical trials, assessing therapeutic efficacy and/or re-staging disease.